Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Regulatory update: mepolizumab for the treatment of hypereosinophilic syndrome (HES)
GSK has notified EMA of decision to withdraw MAA in the EU for mepolizumab for the treatment of hypereosinophilic syndrome (HES).
-
Amgen to collaborate with GSK to commercialize denosumab in Europe for postmenopausal osteoporosis (PMO)
Amgen to retain full rights for denosumab in the United States and Canada and for oncology indications in Europe.
-
GlaxoSmithKline completes acquisition of Stiefel
GSK creates new world-leading specialist dermatology business with revenues of approximately $1.5 billion
-
Results announcement for the second quarter 2009
See the quarterly results page for more information
-
GSK and Enigma Diagnostics announce commercial partnership to develop point-of-care influenza diagnostics
GSK & Enigma have signed agreements to develop and supply influenza tests to identify virus strains using its real-time PCR technology.
-
Antiviral activity of S/GSK1349572, the only once-daily, unboosted integrase inhibitor in clinical development, evaluated in phase 2 study
GSK announced results from Phase 2a study evaluating antiviral activity of INI, S/GSK1349572, results presented at IAS Conference.
-
Human Genome Sciences and GlaxoSmithKline announce positive Phase 3 study results for Benlysta™ in systemic lupus erythematosus
GSK & HGS announced that Benlysta met the primary endpoint in BLISS-52, Phase 3 trials in patients with serologically active SLE.
-
GSK announces new commitments to fight HIV/AIDS in Sub-Saharan Africa - special focus on care and treatment of children
Positive Action for Children Fund created with $80 million available over 10 years to help prevent mother-to-child transmission of HIV.
-
WHO grants prequalification to Cervarix®: GSK’s vaccine to help combat cervical cancer in developing nations
WHO awarded prequalification to Cervarix, cervical cancer vaccine, decision is for agencies to purchase the vaccine in developing countries
-
Alnylam joins GSK in donating intellectual property to patent pool for neglected tropical diseases
First company to join the pool since creation in March 2009
-
Landmark study for GSK’s cervical cancer vaccine published in The Lancet
Largest efficacy trial of a cervical cancer vaccine showed Cervarix® protects against the five most common cancer-causing virus types
-
GSK further extends its product portfolio in the Middle East and North Africa
GSK announced it's acquired the generics business of BMS in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m.
-
Seretide: Irish patent litigation update
GSK announced, Commercial Court in Dublin, Ireland, ruled in patent litigation regarding GSK8217, Seretide, treatment for asthma and COPD.
-
Regulatory update for REZONIC™ (casopitant mesylate)
GSK confirmed today that it has received a complete response letterfrom the FDA related to the application for casopitant
-
GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs
GlaxoSmithKline (LSE: GSK) and Chroma Therapeutics Limited announced today a collaboration to develop macrophage-targeted compounds.
-
FDA extends review of Arzerra™ (ofatumumab)
GSK & Genmab announced, FDA informed the companies they have extended the action date for the ofatumumab BLA application by three months.
-
GSK announces a strategic alliance with Dr. Reddy’s to further accelerate sales growth in emerging markets
GSK announced an agreement with Dr. Reddy's to develop and market selected products across a number of emerging markets, excluding India.
-
GlaxoSmithKline update: A (H1N1) influenza
WHO raises influenza pandemic alert to phase 6
-
GSK and Shenzhen Neptunus create new alliance to develop and manufacture influenza vaccines in China
GSK announced it's entered into JV with Neptunus focused on developing and manufacturing influenza vaccines for the Chinese market.
-
Large, long-term study shows Avandia has no increased overall cardiovascular risk compared to other commonly used diabetes medicines
RECORD trial also demonstrates durable blood sugar control over time with Avandia
